Cytokinetics (CYTK) EVP exercises 2,200 options, sells shares

Cytokinetics (CYTK) Form 4 discloses an insider stock option exercise and sale by an executive.

Rhea-AI Filing Summary

Cytokinetics (CYTK) Form 4 discloses an insider stock option exercise and sale by an executive. The company’s Executive Vice President of Research & Development reported exercising stock options for 2,200 shares of common stock at a price of $10.60 per share on 11/18/2025, then selling 2,200 shares of common stock the same day at a price of $66.45 per share.

After these transactions, the executive directly beneficially owned 140,610 shares of Cytokinetics common stock and held 4,400 derivative securities (stock options) following the reported activity. The filing is made by a single reporting person and is a routine disclosure of insider equity transactions.

Insider Trade Summary

Exercise and Sale: 2,200 shares ($123K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 2,200 shs ($146K)

Approx. gross sale proceeds $146K

Approx. exercise cost $23K

Approx. pre-tax spread $123K

Type	Security	Shares	Price	Value
Exercise	Incentive Stock Option (Right to Buy)	2,200	$0.00	$0.00
Exercise	Common Stock	2,200	$10.60	$23K
Sale	Common Stock	2,200	$66.45	$146K

Holdings After Transaction: Incentive Stock Option (Right to Buy) — 4,400 contracts (Direct); Common Stock — 140,610 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cytokinetics (CYTK) report in this Form 4?

The filing reports that the Executive Vice President of Research & Development exercised stock options for 2,200 shares of Cytokinetics common stock at $10.60 per share and sold 2,200 shares of common stock at $66.45 per share on 11/18/2025.

Who is the reporting person in the Cytokinetics (CYTK) Form 4 and what is their role?

The reporting person is an Officer of Cytokinetics, specifically the Executive Vice President of Research & Development, filing as a single reporting person.

How many Cytokinetics (CYTK) shares does the insider own after the reported transactions?

Following the transactions reported on 11/18/2025, the executive directly beneficially owned 140,610 shares of Cytokinetics common stock.

What derivative securities are involved in this Cytokinetics (CYTK) Form 4?

The filing shows an Incentive Stock Option (Right to Buy) with an exercise price of $10.60 per share, covering 2,200 shares of common stock, originally granted on 03/28/2017 and expiring on 02/28/2027. After the transaction, 4,400 derivative securities were beneficially owned.

Was the Cytokinetics (CYTK) Form 4 filed for more than one reporting person?

No. The Form 4 indicates it is filed by one reporting person, not by a group or multiple filers.

What transaction codes are used in this Cytokinetics (CYTK) Form 4?

The filing uses code M to indicate the exercise of stock options for 2,200 shares at $10.60, and code S to indicate the sale of 2,200 shares at $66.45, both dated 11/18/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 04:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		M		2,200	A	$10.6	142,810	D
Common Stock	11/18/2025		S		2,200	D	$66.45	140,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (Right to Buy)	$10.6	11/18/2025		M			2,200	03/28/2017	02/28/2027	Common Stock	2,200	$0	4,400	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.